Some vaginal bacteria may weaken anti-HIV gel: study

June 1, 2017
HIV infecting a human cell. Credit: NIH

Some kinds of vaginal bacteria may interfere with a gel meant to curb the risk of contracting HIV, which infects more than one million women worldwide each year, researchers said Thursday.

The findings in the journal Science were based on a 2010 study of women in South Africa who used the microbicide drug tenofovir, in vaginal gel form, to assess how well it worked at preventing transmission of (HIV).

The drug has shown success in preventing HIV in high-risk men, but studies involving women have been "disappointing," said the report.

A 2010 randomized trial called CAPRISA 004 showed that , applied before and after sex, reduced HIV incidence by 39 percent.

Researchers examined a subset of women who were infected with HIV during the study, even though they used the gel regularly.

Women who became infected with HIV tended to have a dominant bacteria known as Gardnerella vaginalis, which "could rapidly metabolize and break down the active form of the drug," said the report.

Gardnerella vaginalis is associated with a condition known as bacterial vaginosis (BV).

BV is known to increase the risk of HIV because it increases inflammation, disrupts the vaginal wall and impairs wound-healing, and women from sub-Saharan Africa have high prevalence rates of BV, according to background information in the report.

Women with healthier vaginal bacterial compositions—those dominated by the bacteria Lactobacillus—showed three-fold higher protection against HIV than women with different dominant vaginal bacteria compositions.

An accompanying Perspective article in Science pointed out that the research sheds some light on the reasons for the trial's shortcomings, but fails to offer a solution.

Even if women were tested for vaginal , it remains unclear whether the microbiome could be changed to allow for better performance of the gel, since BV returns in nearly 60 percent of women one year after treatment, wrote Susan Tuddenham and Khalil G. Ghanem of the Johns Hopkins University School of Medicine.

In the meantime, the study serves as a reminder that "without a deeper understanding of the structure, function, and dynamics of the vaginal microbiome, successful interventions to optimize it and improve 's health will remain elusive."

Explore further: Vaginal bacteria can trigger recurrent UTIs, study shows

More information: N.R. Klatt el al., "Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women," Science (2017). science.sciencemag.org/cgi/doi … 1126/science.aai9383

S. Tuddenham el al., "A microbiome variable in the HIV-prevention equation," Science (2017). science.sciencemag.org/cgi/doi … 1126/science.aan6103

Related Stories

Vaginal bacteria can trigger recurrent UTIs, study shows

March 30, 2017
About half of all women will experience urinary tract infections in their lifetimes, and despite treatment, about a quarter will develop recurrent infections within six months of initial infection.

New evidence on why young women in South Africa are at high risk of HIV infection

July 18, 2016
Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, ...

Oral probiotics have no impact on vaginal health in pregnancy

November 1, 2016
(HealthDay)—For pregnant women, probiotics have no effect on vaginal health, according to a study published in the November issue of the American Journal of Obstetrics & Gynecology.

Certain species of vaginal bacteria can increase a woman's susceptibility to HIV

January 10, 2017
Specific bacteria living in the human vagina may play a previously unrecognized role in the sexual transmission of HIV. Ragon Institute researchers, working with young, healthy, South African women, found that individuals ...

Vaginal estriol gel helps women recover after surgery for pelvic organ prolapse

March 29, 2017
Pelvic organ prolapse is estimated to affect up to one-half of all women, causing pain and interfering with sexual function. A new study demonstrates how an ultralow dose of vaginal estriol gel used before and after pelvic ...

Abnormal pap posthysterectomy for 30 percent of HIV+ women

June 14, 2016
(HealthDay)—About one-in-three HIV-infected women with no prehysterectomy history of abnormal Pap results have abnormal vaginal Pap results after hysterectomy, according to a study published in the July issue of Obstetrics ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.